Hunan Fangsheng Pharmaceutical (603998.SH): The clinical trial of Rulogoli tablets has been approved.
Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "...
Hunan Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng") received approval from the National Medical Products Administration for the research and development project of Rilugolix tablets, a chemical generic drug. The approval allows the product to conduct clinical trials for prostate cancer.
Related Articles
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
